PDE-5 Inhibitors for BPH-Associated LUTS

Title:PDE-5 Inhibitors for BPH-Associated LUTS

Volume: 16 Issue: 11

Author(s): Philip Brousil, Majid Shabbir, E. Zacharakis and Arun Sahai

Affiliation:

Keywords: Benign prostatic hyperplasia, LUTS, PDE5 inhibitors, erectile dysfunction.

Abstract: Lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH-LUTS) are a highly prevalent problem, and with considerable burden to quality of life. Evidence has emerged that a strong correlation exists in men suffering both BPH-LUTS and erectile dysfunction (ED). Phosphodiesterase type 5 inhibitors (PDE5i) have been shown to be highly effective in treating ED and more recently there is evidence that men with LUTS also benefit. In this review article we discuss the common pathogenic pathways of ED and LUTS, the scientific basis of PDE5i use, the efficacy of PDE5i in LUTS either as monotherapy or in combination with other established medications used in LUTS.

Cite this article as:

Brousil Philip, Shabbir Majid, Zacharakis E. and Sahai Arun, PDE-5 Inhibitors for BPH-Associated LUTS, Current Drug Targets 2015; 16 (11) . https://dx.doi.org/10.2174/138945011611151013164756